Exelixis, Inc. reports third quarter 2026 financial results and provides corporate updates
Exelixis, Inc. reported its financial results for the third quarter of 2026, with total revenues reaching $658.7 million, ...
Model output · Signal date 2026-11-06
Exelixis, Inc. (EXEL) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 4891 stocks scored
Rank correlation · 90D
-1.0%
Spearman, 357 dates
Market Cap
$16.77B
large-cap · #8 of 60 peers
Summary
Exelixis, Inc. (EXEL) stock forecast summary
Our AI scores Exelixis, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Exelixis, Inc. is a large-cap company with a market capitalization of $16.77B. It ranks number 8 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
For EXEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -1.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, EXEL included.
Price
EXEL price chart and AI forecast
Cross-section · 2026-10-30
How EXEL ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-10-02
Exelixis, Inc. (EXEL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | EXEL | Rank |
|---|---|---|
| Market Cap | $16.77B | 8/60 |
| P/E Ratio | 24.72x | 10/16 |
| P/B Ratio | 9.14x | 14/48 |
| EPS | $2.78 | – |
| Book Value/Share | $7.52 | – |
| Revenue/Share | $9.61 | – |
| FCF/Share | $3.92 | – |
Profitability & Margins
| Metric | EXEL | Rank |
|---|---|---|
| ROE | 42.7% | 3/44 |
| ROA | 31.1% | 2/47 |
| ROIC | 41.5% | 3/52 |
| Gross Margin | 96.4% | 5/24 |
| Operating Margin | 37.6% | 5/41 |
| Net Margin | 33.7% | 3/36 |
| EBT Margin | 37.6% | 5/43 |
| Tax Rate | 18.2% | – |
Financial Health
| Metric | EXEL | Rank |
|---|---|---|
| Current Ratio | 3.21x | 44/59 |
| Quick Ratio | 3.14x | 18/30 |
| D/E Ratio | 0.37x | 28/52 |
| Financial Leverage | 1.37x | 27/51 |
| Interest Coverage | 6.4x | 9/36 |
| Working Capital | $910M | 17/58 |
Cash Flow
| Metric | EXEL | Rank |
|---|---|---|
| Operating Cash Flow | $884M | 7/56 |
| Free Cash Flow | $957M | 6/49 |
| Capital Spending | $73M | 1/49 |
| OCF Growth YoY | 26.3% | 8/16 |
| FCF Growth YoY | 42.5% | 8/16 |
| FCF/Sales | 40.8% | 5/32 |
| CapEx/Sales | 3.1% | 16/32 |
Operational Efficiency
| Metric | EXEL | Rank |
|---|---|---|
| Asset Turnover | 0.93x | 7/37 |
| Receivables Turnover | 7.1x | 8/23 |
| Inventory Turnover | 2.8x | 11/23 |
| Fixed Assets Turnover | 26.9x | 7/38 |
| Days Sales Outstanding | 51 days | 16/23 |
| Days Inventory | 130 days | 13/23 |
| Payables Period | 134 days | 7/26 |
| Cash Conversion Cycle | 47 days | 12/18 |
Income Statement
| Metric | EXEL | Rank |
|---|---|---|
| Total Revenue | $2.35B | 6/38 |
| Operating Income | $872M | 5/53 |
| Net Income | $783M | 4/47 |
| R&D Expense | $825M | 10/55 |
| SG&A Expense | $519M | 8/23 |
| Cost of Goods Sold | $84M | 17/27 |
Dividend & Shareholder Information
| Metric | EXEL | Rank |
|---|---|---|
| Shares Outstanding | 244M | – |
| Net Income Growth | 50.1% | 4/11 |
| EPS Growth | 58.0% | 2/15 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.32B | 52.6% of assets |
| Cash & Short-term Investments | $305M | 12.1% of assets |
| Accounts Receivable | $328M | 13.1% of assets |
| Inventory | $30M | 1.2% of assets |
| Total Liabilities | $680M | 27.0% of assets |
| Short-term Debt | $381M | 15.2% of assets |
Quarterly Financial Reports
EXEL quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Exelixis, Inc. (EXEL) industry peers
Companies classified under the same SEC industry code as Exelixis, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| EXEL Exelixis, Inc. | $16.77B | |
| AMGN Amgen Inc | $248.84B | |
| GILD Gilead Sciences, Inc. | $207.84B | |
| MRNA Moderna, Inc. | $96.40B | |
| ARGX Argenx Se | $55.37B | |
| RVMD Revolution Medicines, Inc. | $38.08B | |
| BIIB Biogen Inc. | $36.06B | |
| BNTX Biontech Se | $21.71B | |
| NBIX Neurocrine Biosciences Inc | $16.24B | |
| HALO Halozyme Therapeutics, Inc. | $13.96B | |
| TECH Bio-Techne Corp | $11.41B | |
| QGEN Qiagen N.V. | $11.03B | |
| KYMR Kymera Therapeutics, Inc. | $10.94B | |
| RGEN Repligen Corp | $10.77B | |
| PCVX Vaxcyte, Inc. | $9.21B | |
| KRYS Krystal Biotech, Inc. | $8.90B | |
| IBRX Immunitybio, Inc. | $8.49B | |
| TWST Twist Bioscience Corp | $7.56B | |
| IMVT Immunovant, Inc. | $5.86B | |
| CGON Cg Oncology, Inc. | $5.74B | |
| KOD Kodiak Sciences Inc. | $5.72B | |
| SRRK Scholar Rock Holding Corp | $5.54B | |
| CRSP Crispr Therapeutics Ag | $4.70B | |
| ADPT Adaptive Biotechnologies Corp | $4.28B | |
| RLAY Relay Therapeutics, Inc. | $3.73B | |
| IOVA Iovance Biotherapeutics, Inc. | $3.51B | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.33B | |
| DNLI Denali Therapeutics Inc. | $3.15B | |
| ADMA Adma Biologics, Inc. | $2.96B | |
| BEAM Beam Therapeutics Inc. | $2.67B | |
| RXRX Recursion Pharmaceuticals, Inc. | $2.18B | |
| COAG Hemab Therapeutics Holdings, Inc. | $2.13B | |
| VCEL Vericel Corp | $2.10B | |
| LIFE Atyr Pharma Inc | $2.08B | |
| BCRX Biocryst Pharmaceuticals Inc | $1.95B | |
| REPL Replimune Group, Inc. | $1.90B | |
| VIR Vir Biotechnology, Inc. | $1.86B | |
| MAZE Maze Therapeutics, Inc. | $1.81B | |
| MESO Mesoblast Ltd | $1.81B | |
| ALVO Alvotech | $1.62B | |
| NVAX Novavax Inc | $1.61B | |
| IMCR Immunocore Holdings Plc | $1.46B | |
| TSHA Taysha Gene Therapies, Inc. | $1.33B | |
| VOR Vor Biopharma Inc. | $1.15B | |
| CGEM Cullinan Therapeutics, Inc. | $1.01B | |
| ODTX Odyssey Therapeutics, Inc. | $907M | |
| GLUE Monte Rosa Therapeutics, Inc. | $874M | |
| IMTX Immatics N.V. | $829M | |
| MGTX Meiragtx Holdings Plc | $817M | |
| PRME Prime Medicine, Inc. | $807M | |
| SANA Sana Biotechnology, Inc. | $700M | |
| SLBT Sl Science Holding Ltd | $679M | |
| DNA Ginkgo Bioworks Holdings, Inc. | $671M | |
| SLDB Solid Biosciences Inc. | $663M | |
| AURA Aura Biosciences, Inc. | $657M | |
| FDMT 4d Molecular Therapeutics, Inc. | $621M | |
| DBVT Dbv Technologies S.A. | $616M | |
| CADL Candel Therapeutics, Inc. | $615M | |
| VALN Valneva Se | $551M | |
| ENTX Entera Bio Ltd. | $518M |
Where EXEL sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Exelixis, Inc. (EXEL) stock news
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2025 Financial Results Conference Call. My name is [ Towanda ], and I'll be your operator for today. As a ...
Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?
Is EXEL a good stock to buy? We came across a bullish thesis on Exelixis, Inc. on TradersPro’s Substack. In this article, we ...
FAQ
Exelixis, Inc. (EXEL) stock forecast FAQ
What is the Exelixis, Inc. (EXEL) stock forecast?
Our AI scores Exelixis, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Exelixis, Inc. stock predictions?
For EXEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -1.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Exelixis, Inc. forecasts updated?
Exelixis, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Exelixis, Inc.'s industry peers?
60 issuers in our coverage, EXEL included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.